As CRISPR–Cas adoption soars, summit calls for genome editing oversight
By Eric Smalley,
Nature Biotechnology
| 06. 06. 2018
Researchers are using a pair of initiatives, launched within a few days of each other, to widen the discussion about genome editing oversight to include countries often excluded from the conversation. At a meeting in Paris on March 23, a group of European biotech researchers launched the Association for Responsible Research and Innovation in Genome Editing (ARRIGE). Two days earlier, Nature published a call by two science, technology and society scholars to establish a global gene editing observatory (Nature 555, 435–437, 2018). The initiatives...
Related Articles
By Scott Solomon, The MIT Press Reader | 02.12.2026
Chris Mason is a man in a hurry.
“Sometimes walking from the subway to the lab takes too long, so I’ll start running,” he told me over breakfast at a bistro near his home in Brooklyn on a crisp...
By Zachary Brennan, Endpoints News | 02.23.2026
The FDA is spelling out the details of a new pathway to help speed personalized cell and gene therapies to market for rare diseases.
Monday’s long-awaited draft guidance outlines the agency’s “plausible mechanism” framework, a pathway FDA Commissioner Marty Makary...
By Amy Feldman, Forbes | 02.17.2026
"Jennifer Doudna" by Duncan Hull for the Royal Society via Wikimedia Commons licensed under CC by SA 3.0
Soon after KJ Muldoon was born in August 2024, he was lethargic and wouldn’t eat. His worried doctors realized his ammonia...
By David Jensen, California Stem Cell Report | 02.10.2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The...
